

Startup Labs at the Vienna BioCenter

VIENNA The Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in biotechnology by the next coming generation of bio-entrepreneurs. Key assets include close proximity to outstanding academic research and highly successful innovators as well as access to cutting-edge research infrastructure.



Vienna celebrated the opening of affordable, flexible co-working labs

Vienna is one of Europe's leading metropolises for biotech start-ups. Excellent academic education and research, strong regional sites by global players such as Boehringer Ingelheim, Octapharma, Pfizer and Takeda and world-renowned hospitals are key ingredients in the Austrian recipe of success. Proven funding programs such as PreSeed and Seedfinancing by the Austrian promotional bank Austria Wirtschaftsservice, experienced investment management teams at federal and regional level, and a research tax premium of 14% are additional ingredients. The Vienna Business Agency is now offering new co-working labs to facilitate start-up processes.

Hotspot Vienna BioCenter

At the Vienna BioCenter, new business ideas are evaluated and implemented in the immediate vicinity of IMP, IMBA; GMI and the Max Perutz Labs that provide home to world-renowned research

groups. Start-ups also can learn from business strategies followed by their experienced neighbors, including Apeiron, Hookipa, Lexogen, Thermo Fisher Scientific and Valneva. The new Startup Labs are in high demand with the first group of users including:

- › a:head bio AG
- › Ablevia biotech GmbH
- › G.ST Antivirals GmbH
- › Miti Biosystems GmbH
- › MyeloPro Diagnostics and Research GmbH
- › Pregenerate GmbH
- › Proxygen GmbH
- › THT Biomaterials GmbH
- › QUANTRO Therapeutics GmbH

These companies strive to create business cases based on the latest scientific findings. Their focus areas are highly diverse and range from drug development to screening platforms and various specialized services. Indications include arthritis, auto-immune disorders, can-



cer, brain diseases and viral infections. Boehringer Ingelheim supports the Startup Labs Program and fosters excellent life science innovation. It has awarded the first BI Innovation Prize in Europe to the CeMM-spin-off company Proxygen.

New executive board member

Philipp Hainzl oversees the Startup Labs. Recently, he also joined the LISAvienna executive board where he represents the Vienna Business Agency. He and Johannes Sarx from the Austrian promotional bank Austria Wirtschaftsservice are now jointly responsible for Vienna's thriving life science cluster.

CONTACT

Johannes Sarx and Philipp Hainzl
office@LISAvienna.at
www.LISAvienna.at

